New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
05:50 EDTAET, UNH, HNT, WLPManaged Care sector downgraded to Neutral at Deutsche Bank
Deutsche Bank downgraded its rating on the Managed Care sector to Neutral from Positive citing higher underwriting risks and a lack of catalysts. The firm downgraded shares of UnitedHealth (UNH) and Wellpoint (WLP) to Hold from Buy, upgraded shares of Health Net (HNT) to Hold from Sell, and kept a Buy rating on shares of Aetna (AET), its top pick in the space.
News For UNH;WLP;HNT;AET From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
07:42 EDTAETAetna removed from US Focus List at Credit Suisse
Subscribe for More Information
May 19, 2015
12:04 EDTAETAnthem CFO says 'good time' for 'meaningful' acquisition, Reuters reports
Subscribe for More Information
May 18, 2015
09:33 EDTAETAetna repeats FY15 operating EPS view $7.20-$7.40, consensus $7.38
Subscribe for More Information
May 15, 2015
16:51 EDTAETGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
May 14, 2015
07:33 EDTUNHUnitedHealth would consider Optum spinoff if benefits erode, says UBS
Subscribe for More Information
May 13, 2015
10:18 EDTAETAnalyst says sell Humana amid 'wishful' takeover speculation
Subscribe for More Information
May 12, 2015
13:03 EDTAETAetna repeats view of FY15 operating EPS $7.20-$7.40, consensus $7.38
Subscribe for More Information
11:53 EDTAETAnalyst predicts large transaction 'imminent' for Aetna
Subscribe for More Information
10:04 EDTAETHigh option volume stocks
Subscribe for More Information
09:53 EDTAETAetna merger with Cigna or Humana likely 'imminent,' says Leerink
Subscribe for More Information
07:35 EDTHNTBofA/Merrill to hold a conference
Subscribe for More Information
May 11, 2015
15:06 EDTAETAetna backs FY15 operating EPS $7.20-$7.40, consensus $7.38
In a regulatory filing earlier, Aetna reported that during upcoming investor meetings in May, the company expects to reaffirm its FY15 operating EPS guidance of $7.20-$7.40. Current FY15 EPS consensus is $7.38.
07:40 EDTUNHFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertexís Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasnít announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
07:13 EDTUNHUnitedHealth management to meet with UBS
Subscribe for More Information
06:51 EDTAETAetna management to meet with Leerink
Meeting to be held in Hartford, CT on May 11 hosted by Leerink.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use